SSRX Share Price

Open 16.61 Change Price %
High 16.64 1 Day 0.00 0.00
Low 16.59 1 Week 0.00 0.00
Close 16.59 1 Month 0.00 0.00
Volume 253819 1 Year 0.00 0.00
52 Week High 15.84
52 Week Low 5.26
SSRX Important Levels
Resistance 2 16.64
Resistance 1 16.62
Pivot 16.61
Support 1 16.56
Support 2 16.54
NASDAQ USA Most Active Stocks
FNFG 10.18 -0.20%
FTR 1.94 -8.06%
FTR 1.94 -8.06%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
BBEP 0.12 0.00%
GTAT 0.44 0.00%
SUSQ 14.20 -0.77%
MU 26.47 1.57%
More..
NASDAQ USA Top Gainers Stocks
PGRX 0.06 200.00%
LLEN 0.02 100.00%
LOCM 0.09 50.00%
WRES 0.09 28.57%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
OTT 2.39 25.13%
HAUP 0.06 20.00%
FALC 0.36 16.13%
OTIV 1.70 15.65%
More..
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
VALV 0.02 -50.00%
QTWW 0.08 -50.00%
SPIR 0.01 -50.00%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
More..

3SBio Inc. (NASDAQ: SSRX)

SSRX Technical Analysis 5
As on 29th May 2013 SSRX Share Price closed @ 16.59 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 13.73 & Strong Buy for SHORT-TERM with Stoploss of 15.80 we also expect STOCK to react on Following IMPORTANT LEVELS.
SSRX Target for March
1st Target up-side N/A
2nd Target up-side N/A
3rd Target up-side N/A
1st Target down-side N/A
2nd Target down-side N/A
3rd Target down-side N/A
SSRX Other Details
Segment EQ
Market Capital 295193888.00
Sector Consumer Durables Major Pharmaceuticals
Industry
Offical website
SSRX Address
SSRX
N/A
SSRX Latest News
3SBio Inc (SSRX) Upgraded at Goldman Sachs Group Inc   BBNS   - 23rd Mar 17
3SBio Inc (SSRX) Stock Rating Upgraded by Goldman Sachs Group Inc   Chaffey Breeze   - 22nd Mar 17
3SBio Inc (SSRX) Upgraded to “Buy” at Goldman Sachs Group Inc   The Cerbat Gem   - 21st Mar 17
3SBio Inc. Appoints Dr. Zhenping Zhu as President of Research & Development ...   PR Newswire (press release)   - 09th Jan 17
3SBio Inc. Announces Expansion of its Leadership Team   PR Newswire (press release)   - 04th Mar 16
3SBio Signs Exclusive Patent License Agreement for ALT-P7, an Antibody-drug ...   PR Newswire (press release)   - 12th Oct 15
3SBio Inc. Exclusively Licenses Pegsiticase (Uricase PEG-20) to Selecta ...   PR Newswire (press release)   - 18th Jun 14
3SBio Inc. Announces Completion of Merger   PR Newswire (press release)   - 30th May 13
3SBio Inc. Enters Into Merger Agreement For "Going Private" Transaction   PR Newswire (press release)   - 08th Feb 13
3SBio Inc. Announces Receipt of "Going Private" Proposal at $15 Per ADS   PR Newswire (press release)   - 12th Sep 12
Interactive Technical Analysis Chart 3SBio Inc. ( SSRX NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on 3SBio Inc.
SSRX Business Profile
3SBio Inc. is a biotechnology company in the People's Republic of China with research and development, manufacturing, and marketing capabilities focusing on bio-pharmaceutical products. The Company recombinant, or genetically engineered, protein-based products and product candidates are designed to address markets with unmet medical needs in nephrology, oncology, supportive cancer care, inflammation and infectious diseases. Its principal products are EPIAO and TPIAO. In addition, it has two legacy products, Intefen and Inleusin; and an in-licensed product, Iron Sucrose Supplement. The Company focuses on its research and development efforts on both novel and validated protein-based therapeutics for the treatment of diseases in the areas of nephrology, oncology, supportive cancer care, inflammation and infectious diseases, and other selected areas. In May 2013, the Company merged with Decade Sunshine Limited and Decade Sunshine Merger Sub.